Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis.

  1. Inicio
  2. »
  3. Sin categoría
  4. »
  5. Lysophosphatidic acid receptor inhibition as a new multipronged treatment for...

Pharmacological inhibition of LPA1 receptor in the K/BxN serum-transfer arthritis model led to reduction of severity of arthritis involving multiple mechanisms, increased apoptosis, reduced inflammatory mediators and proteins involved in bone remodelling, that show LPA1 as a very promising target in rheumatoid arthritis treatment.

Autor: Orosa B, García S, Martínez P, González A, Gómez-Reino JJ, Conde C.

Patrocinadores de la web
Lilly
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Meiji Pharma
Faes Farma